艾塞那肽
甘精胰岛素
医学
内科学
2型糖尿病
内分泌学
胃肠病学
胰岛素
糖尿病
作者
Lin Li,Jian Gao,Ruwen Wang,Jiaqin Yan,Jindan Zhang,Lin Hao,Sheng-Xiang Rao,Xiuzhong Yao,Wanlong Wu,Hua Bian,Z. Zhang,Jiaojiao Liu,Sisi Guo,Xin Gao,Hongmei Yan
出处
期刊:Experimental and Clinical Endocrinology & Diabetes
[Georg Thieme Verlag KG]
日期:2023-07-31
卷期号:131 (11): 583-588
摘要
Abstract Aim This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm2) were obtained with the cross-sectional Dixonfat magnetic resonance images at the fourth lumber vertebra. Results There were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (–215.52, 280.80) mm2 in the insulin glargine group and decrease by 149.09 (322.90–56.39) mm2 in the exenatide group (both p>0.05). Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm2) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI<28 kg/m2 (p0.031) after adjusting for gender, age, and research center. Interaction analysis showed an interaction between BMI and treatment (p0.009). However, no interaction was observed among subgroups with a BMI≥28 kg/m2 or with different genders and ages. Conclusion Compared to exenatide, insulin glargine can relativity increase PMA in patients with T2DM having BMI<28 kg/m2 and NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI